Ambrisentan NDC 51407-595

NDC codes

FDA NDC Directory

Product NDC (as listed)51407-595Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51407-0595Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51407-595-30	51407059530	30 TABLET, FILM COATED in 1 BOTTLE (51407-595-30)Marketed from Nov 17, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ambrisentan
Generic name (nonproprietary): ambrisentan
Active ingredients: Ambrisentan — 10 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Golden State Medical Supply, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210701
Marketing start: May 19, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Endothelin Receptor Antagonists (Mechanism)
Identifiers: Product ID 51407-595_496834ab-a472-147d-e063-6394a90a12f3SPL ID 496834ab-a472-147d-e063-6394a90a12f3SPL set ID 4396bab5-2851-62ef-e063-6294a90af76eRxCUI 722116, 722122UNII HW6NV07QEC
Pharmacologic class: Endothelin Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N451407059530 followed by a unit qualifier and the quantity

Package 51407-0595-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 27, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%). Ambrisentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients: To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients wit…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210701

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210701
Product	Strength	Form · route	Labeler	Product NDC
Ambrisentan	Ambrisentan 5 mg/1	Tablet, Film coatedOral	Golden State Medical Supply, Inc.	51407-594
Ambrisentan	Ambrisentan 5 mg/1	Tablet, Film coatedOral	Apotex Corp.	60505-4552
Ambrisentan	Ambrisentan 10 mg/1	Tablet, Film coatedOral	Apotex Corp.	60505-4553